Meropenem for Pseudomonas Wound Infection
For Pseudomonas aeruginosa wound infections, administer meropenem 1 gram IV every 8 hours by infusion over 15-30 minutes, with treatment duration of 7-14 days depending on clinical response.
Standard Dosing Regimen
The FDA-approved dosing for complicated skin and soft tissue infections (cSSSI) is 500 mg every 8 hours, but when Pseudomonas aeruginosa is the causative pathogen, the dose must be increased to 1 gram every 8 hours 1. This higher dose is critical because P. aeruginosa typically has higher MICs at the susceptibility breakpoint (≤2 mg/L per EUCAST), requiring more aggressive dosing to achieve adequate pharmacokinetic/pharmacodynamic targets 2.
Administration Method
- Preferred: IV infusion over 15-30 minutes 1
- Alternative: IV bolus over 3-5 minutes for 1 gram doses (though infusion is preferred for optimal tissue penetration) 1
- Consider extended infusion (3-4 hours) or continuous infusion in critically ill patients or when MIC approaches 4 mg/L, as this significantly improves target attainment 3, 4
Renal Dose Adjustments
Dosing must be adjusted based on creatinine clearance (CrCl), calculated using the Cockcroft-Gault equation 1:
| CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >50 | 1 gram | Every 8 hours |
| 26-50 | 1 gram | Every 12 hours |
| 10-25 | 500 mg | Every 12 hours |
| <10 | 500 mg | Every 24 hours |
Critical Caveat for Elderly Patients
In elderly patients with low body weight, evaluate both Cockcroft-Gault CrCl AND MDRD eGFR when significant discrepancy exists between the two values 5. Using CrCl alone may lead to inappropriate dose reduction and treatment failure, particularly in frail elderly patients where body surface area-based calculations (MDRD) may be more accurate 5.
Augmented Renal Clearance (ARC)
Critically ill patients with CrCl >130 mL/min require intensified regimens: 2 grams every 8 hours with extended infusion (3-4 hours) or continuous infusion to achieve adequate exposure 4. Standard dosing fails to achieve PK/PD targets in this population 2, 4.
Treatment Duration
7-14 days is the recommended duration for most bacterial skin and soft tissue infections 6. The specific duration should be based on:
- 7-10 days: Uncomplicated wound infections with good source control and clinical improvement
- 10-14 days: Deep tissue involvement, bacteremia, or delayed clinical response
- Shorter courses (5-7 days): May be adequate if source control is achieved within 24 hours and clinical response is rapid 7
Therapeutic Drug Monitoring Considerations
While not routinely required, TDM should be considered in:
- Critically ill patients: Target trough (Cmin) ≥5.3 mg/L for general infections, ≥7.3 mg/L for bloodstream infections 3
- Patients with ARC: To ensure adequate exposure despite enhanced clearance 4
- Treatment failure: To distinguish between inadequate dosing versus resistant organisms 5
The PK/PD target for meropenem is 40% fT>MIC for bacteriostatic effect, but 100% fT>MIC is preferred for critically ill patients or immunocompromised hosts 2, 8.
Combination Therapy
For severe Pseudomonas infections, particularly in necrotizing soft tissue infections, consider adding an aminoglycoside (gentamicin 5-7 mg/kg/day) or antipseudomonal fluoroquinolone (ciprofloxacin 400 mg IV every 12 hours) during the first 3-5 days 9, 10. This approach is especially important when:
- Patient is critically ill with systemic toxicity
- Concern for multidrug-resistant Pseudomonas
- Necrotizing fasciitis or deep tissue involvement
Common Pitfalls to Avoid
Using standard 500 mg dosing for Pseudomonas: This is the most critical error—always use 1 gram every 8 hours 1
Over-adjusting for renal function in elderly: Don't rely solely on Cockcroft-Gault in frail elderly patients with low body weight 5
Inadequate dosing in ARC patients: Critically ill patients often have enhanced clearance requiring higher doses or extended/continuous infusions 2, 4
Premature discontinuation: Ensure at least 7 days of therapy with documented clinical improvement before stopping 6